Cargando…
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials w...
Autores principales: | Saglio, Giuseppe, le Coutre, Philipp, Cortes, Jorge, Mayer, Jiří, Rowlings, Philip, Mahon, François-Xavier, Kroog, Glenn, Gooden, Kyna, Subar, Milayna, Shah, Neil P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486782/ https://www.ncbi.nlm.nih.gov/pubmed/28534184 http://dx.doi.org/10.1007/s00277-017-3012-z |
Ejemplares similares
-
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016) -
Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
por: le Coutre, P D, et al.
Publicado: (2016) -
Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018) -
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007) -
Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
por: Shah, Neil P., et al.
Publicado: (2016)